NCT05670951View on ClinicalTrials.gov

Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

PHASE3RecruitingINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

May 31, 2029

Conditions
Intestinal Malabsorption
Interventions
DRUG

ELGN-2112

Human insulin \[rDNA\]

DRUG

Placebo

Placebo

Trial Locations (1)

4244916

RECRUITING

Laniado Hospital, Netanya

Sponsors

Lead Sponsor

Elgan Pharma Ltd.
All Listed Sponsors
lead

Elgan Pharma Ltd.

INDUSTRY